Status:
COMPLETED
A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Collaborating Sponsors:
Loxo Oncology, Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to measure how much of LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered in fasting and fed states in healthy particip...
Eligibility Criteria
Inclusion
- Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
- Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
Exclusion
- Females who are lactating or of childbearing potential
- Clinically significant history of any drug sensitivity, drug allergy, or food allergy
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 23 2023
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT06028425
Start Date
September 1 2023
End Date
December 23 2023
Last Update
July 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fortrea Clinical Research Unit
Daytona Beach, Florida, United States, 32117